TOUR006 Study: This study is for people with chronic kidney disease and high levels of hs-CRP (a marker in the blood that shows inflammation). The study looks at the safety and effects of a new medicine called TOUR006, given as a shot under the skin every month or every three months. TOUR006 is a type of medicine called a monoclonal antibody that targets a protein called IL-6, which is involved in causing inflammation.

Eligibility: Adults 18 and older with chronic kidney disease and a certain level of hs-CRP can participate. You must have received a COVID-19 vaccine at least 30 days before joining. You should not have any active infections or recent serious health issues.

Key Points:

• The study involves getting a shot monthly or quarterly.
• You must visit the study site for check-ups.
• Be aware of potential side effects or risks involved.